Genetic testing for prostate cancer. Willingness and predictors of interest. Cancer Pract 2000;8:82-86.Diefenbach, MA, Schnoll, RA, Miller, SM, Brower, L (2000) Genetic testing prostate cancer: Willingness and
Understanding the chemistry underlying the interaction of pharmacological chaperones with their target proteins will facilitate the design of more efficient drugs with greater therapeutic potential.doi:10.5694/mja18.00324Brooks DougOlver Ian NEsterman Adrian JThe Medical journal of Australia...
Oncotype Dx –Once a prostate biopsy has been done, the tissue samples can be used for this further analysis. Based on the activity of certain prostate cancer genes, Oncotype Dx assigns a Genomic Prostate Score. The score indicates the probability that, if left untreated, the cancer would prog...
being tested for prostate cancer overall. For example: ‘I tried not to think about the PSA blood test’ (time-point 1); ‘I tried not to think about going for my biopsy’ (time-point 2); ‘I tried not to think about getting my biopsy results’ (time-point 3) and ‘I tried not...
Online questionnaire survey, with a sample of 421 GPs randomly selected from a database of GPs across the UK.95% (400/421) of GPs responded. 76% of GPs reported having performed a PSA test for an asymptomatic man at least once in the previous three month
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relati
We describe the rationale, design and recruitment of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) trial, a UK-wide cluster randomised controlled trial investigating the effectiveness and cost-effectiveness of prostate-specific antigen (PSA) testing. Methods: Seven hundred and...
BMC Family Practice BioMed Central Research article PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK To describe general practitioners' current beliefs, knowledge and self-reported practices in prostate cancer screening, we conducted...
M McCredie, B Cox, "Prostate-specific antigen testing for prostate cancer: The case for informed consent", Medical Journal of Australia, 169, 1998, 9-10.McCredie M, Cox B. Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust. 1998; 169 (1):...
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implication